Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Next Previous
Trial Profile

Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary) ; Venlafaxine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLUTION
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 06 Nov 2019 Results assessing treatment success of vortioxetine versus venlafaxine XR and cost-Effectiveness were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 24 Sep 2019 Results (n=186) of pooled analysis of this and other two studies (NCT01676571 and NCT02386488) assessing pharmacokinetic analysis in Chinese and non-Chinese healthy subjects, published in the Advances in Therapy.
    • 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top